Pictet Asset Management Ltd. increased its position in China Biologic Products, Inc. (NASDAQ:CBPO) by 12.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,800 shares of the biopharmaceutical company’s stock after buying an additional 2,200 shares during the period. Pictet Asset Management Ltd. owned approximately 0.07% of China Biologic Products worth $2,253,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Oppenheimer Asset Management Inc. bought a new position in China Biologic Products during the first quarter worth approximately $156,000. Eqis Capital Management Inc. boosted its position in China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 1,092 shares during the period. Nomura Holdings Inc. bought a new position in China Biologic Products during the first quarter worth approximately $463,000. Gateway Advisory LLC bought a new position in China Biologic Products during the first quarter worth approximately $480,000. Finally, First Trust Advisors LP boosted its position in China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares during the period. 72.91% of the stock is owned by hedge funds and other institutional investors.

China Biologic Products, Inc. (NASDAQ CBPO) opened at 91.24 on Tuesday. The company has a market cap of $2.49 billion, a price-to-earnings ratio of 23.75 and a beta of 1.70. China Biologic Products, Inc. has a one year low of $88.25 and a one year high of $126.47. The company has a 50-day moving average of $98.75 and a 200-day moving average of $106.37.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million during the quarter, compared to analyst estimates of $97.33 million. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. China Biologic Products’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Equities research analysts expect that China Biologic Products, Inc. will post $4.95 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/22/pictet-asset-management-ltd-raises-stake-in-china-biologic-products-inc-cbpo.html.

A number of research analysts have recently commented on the stock. Jefferies Group LLC reissued a “buy” rating on shares of China Biologic Products in a report on Friday, August 4th. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Friday, May 5th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of China Biologic Products in a report on Tuesday, May 30th. They issued a “neutral” rating for the company. Finally, BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $132.00.

About China Biologic Products

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.